🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 16 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
23/12/2015 31,87 33,74 31,34 33,50 +6,08% 7,53% 541.800
22/12/2015 33,35 33,64 31,52 31,58 -4,36% 6,36% 486.500
21/12/2015 32,91 33,16 32,00 33,02 +1,60% 3,52% 677.100
18/12/2015 32,20 33,96 31,04 32,50 +0,00% 9,07% 1.984.500
17/12/2015 34,30 35,40 32,24 32,50 -4,52% 9,21% 712.500
16/12/2015 29,10 34,72 29,10 34,04 +19,02% 19,31% 1.762.400
15/12/2015 27,25 29,29 27,08 28,60 +7,76% 8,09% 892.000
14/12/2015 26,83 27,80 26,12 26,54 -1,34% 6,26% 890.600
11/12/2015 27,39 28,03 26,51 26,90 -4,00% 5,55% 756.800
10/12/2015 27,31 28,46 26,96 28,02 +2,90% 5,49% 437.000
09/12/2015 27,63 28,00 26,95 27,23 -1,52% 3,80% 438.800
08/12/2015 26,18 27,82 26,00 27,65 +4,22% 6,95% 713.000
07/12/2015 27,87 27,90 26,22 26,53 -4,36% 6,03% 677.800
04/12/2015 28,00 28,37 26,14 27,74 -0,50% 7,96% 909.400
03/12/2015 29,02 29,66 27,37 27,88 -3,40% 7,89% 685.700
02/12/2015 29,45 29,75 28,60 28,86 -1,84% 3,90% 425.200
01/12/2015 30,45 30,45 28,75 29,40 -2,13% 5,58% 712.500
30/11/2015 29,98 30,74 28,91 30,04 +1,62% 6,12% 693.500
27/11/2015 29,89 29,89 28,62 29,56 +0,14% 4,25% 438.000
25/11/2015 28,61 30,58 28,13 29,52 -7,02% 8,56% 1.694.600
24/11/2015 30,52 31,80 29,13 31,75 +3,05% 8,75% 961.600
23/11/2015 29,90 31,25 29,15 30,81 +6,24% 7,02% 1.443.900
20/11/2015 27,88 32,12 27,17 29,00 -3,72% 17,75% 2.962.200
19/11/2015 34,61 34,65 30,02 30,12 -13,15% 13,38% 1.486.200
18/11/2015 32,91 34,80 32,75 34,68 +4,81% 6,23% 1.091.900
17/11/2015 30,91 34,24 30,08 33,09 +7,33% 13,46% 1.332.800
16/11/2015 29,88 31,22 29,06 30,83 +1,85% 7,23% 635.900
13/11/2015 28,44 31,14 28,00 30,27 +5,54% 11,04% 631.500
12/11/2015 28,95 29,95 28,23 28,68 +0,03% 5,94% 743.700
11/11/2015 29,25 30,07 28,39 28,67 -2,15% 5,74% 577.100